SCYNEXIS Stock Forecast, Price & News

-0.16 (-1.95 %)
(As of 04/13/2021 10:24 AM ET)
Today's Range
Now: $8.05
50-Day Range
MA: $8.28
52-Week Range
Now: $8.05
Volume4,507 shs
Average Volume639,649 shs
Market Capitalization$166.02 million
P/E RatioN/A
Dividend YieldN/A
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SCYX
Year FoundedN/A



Sales & Book Value

Annual Sales$120,000.00
Book Value$1.32 per share


Net Income$-53,710,000.00


Market Cap$166.02 million
Next Earnings Date5/10/2021 (Estimated)


SCYNEXIS (NASDAQ:SCYX) Price Target Lowered to $40.00 at Aegis
April 12, 2021 |
Form 8-K SCYNEXIS INC For: Feb 19 -
February 23, 2021 |
See More Headlines


Overall MarketRank

1.43 out of 5 stars

Medical Sector

614th out of 2,016 stocks

Pharmaceutical Preparations Industry

284th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
-0.16 (-1.95 %)
(As of 04/13/2021 10:24 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS
or view top-rated stocks.

What stocks does MarketBeat like better than SCYNEXIS?

Wall Street analysts have given SCYNEXIS a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SCYNEXIS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting SCYNEXIS?

SCYNEXIS saw a increase in short interest in the month of February. As of February 26th, there was short interest totaling 1,110,000 shares, an increase of 40.6% from the February 11th total of 789,300 shares. Based on an average daily trading volume, of 672,100 shares, the days-to-cover ratio is presently 1.7 days. Currently, 6.0% of the company's shares are short sold.
View SCYNEXIS's Short Interest

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for SCYNEXIS

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Sunday, March, 28th. The company reported ($3.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.73) by $2.80.
View SCYNEXIS's earnings history

How has SCYNEXIS's stock been impacted by COVID-19?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SCYX shares have increased by 3.2% and is now trading at $8.05.
View which stocks have been most impacted by COVID-19

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

SCYNEXIS shares reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

7 brokerages have issued twelve-month price targets for SCYNEXIS's stock. Their forecasts range from $20.00 to $50.00. On average, they anticipate SCYNEXIS's stock price to reach $30.29 in the next twelve months. This suggests a possible upside of 276.2% from the stock's current price.
View analysts' price targets for SCYNEXIS
or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Dr. Marco Taglietti, CEO, Pres & Director (Age 61, Pay $937.35k)
  • Mr. Eric Francois, Chief Financial Officer (Age 46, Pay $604.91k)
  • Mr. David Gonzalez Angulo, Chief Medical Officer (Age 56, Pay $676.13k)
  • Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Jim Maffezzoli, VP of Marketing & Sales
  • Dr. Rajeshwar Motheram, Sr. VP of Pharmaceutical Devel. & Supply Chain

Who are some of SCYNEXIS's key competitors?

What other stocks do shareholders of SCYNEXIS own?

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $8.05.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $166.02 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 38 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is

Where are SCYNEXIS's headquarters?


How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.